Analysts Offer Predictions for PTCT FY2026 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of PTC Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will post earnings per share of ($2.69) for the year. Cantor Fitzgerald has a “Overweight” rating and a $112.00 price objective on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, topping the consensus estimate of $0.85 by $9.19. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $437.16 million. During the same quarter in the prior year, the firm earned ($1.20) EPS. The firm’s revenue was down 9.6% on a year-over-year basis.

A number of other brokerages also recently issued reports on PTCT. Scotiabank began coverage on PTC Therapeutics in a research report on Friday, March 7th. They set a “sector perform” rating and a $55.00 price objective for the company. Robert W. Baird dropped their target price on PTC Therapeutics from $70.00 to $66.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Bank of America raised PTC Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $55.00 to $68.00 in a research report on Friday, May 9th. Wells Fargo & Company lifted their target price on PTC Therapeutics from $68.00 to $74.00 and gave the company an “overweight” rating in a research report on Tuesday, May 27th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $70.00 target price (up from $67.00) on shares of PTC Therapeutics in a research report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $63.75.

PTC Therapeutics Trading Up 0.1%

Shares of NASDAQ:PTCT opened at $51.74 on Tuesday. The business has a 50-day moving average price of $46.50 and a 200 day moving average price of $47.99. The company has a market capitalization of $4.10 billion, a price-to-earnings ratio of -8.71 and a beta of 0.51. PTC Therapeutics has a 12-month low of $28.72 and a 12-month high of $58.38.

Insider Activity

In other news, CEO Matthew B. Klein sold 2,804 shares of PTC Therapeutics stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $48.74, for a total value of $136,666.96. Following the completion of the transaction, the chief executive officer now owns 273,234 shares in the company, valued at approximately $13,317,425.16. This trade represents a 1.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Lee Scott Golden sold 897 shares of PTC Therapeutics stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $46.95, for a total value of $42,114.15. Following the completion of the transaction, the executive vice president now owns 75,997 shares of the company’s stock, valued at $3,568,059.15. The trade was a 1.17% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,513 shares of company stock worth $578,498. 5.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On PTC Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Strs Ohio purchased a new stake in PTC Therapeutics during the first quarter worth approximately $438,000. Ellsworth Advisors LLC purchased a new stake in PTC Therapeutics during the first quarter worth approximately $588,000. Acadian Asset Management LLC lifted its stake in PTC Therapeutics by 6.1% during the first quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock worth $1,904,000 after purchasing an additional 2,140 shares during the last quarter. Intech Investment Management LLC lifted its stake in PTC Therapeutics by 62.8% during the first quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock worth $2,003,000 after purchasing an additional 15,167 shares during the last quarter. Finally, Bayforest Capital Ltd purchased a new stake in PTC Therapeutics during the first quarter worth approximately $415,000.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.